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Model of Reticuloendothelial Iron Metabolism in Humans: Abnormal Behavior
in Idiopathic Hemochromatosis and in Inflammation
By Georges Fillet, Yves Beguin, and Laurent Baldelli
Iron transport in the reticuloendothelial (RE) system plays a
central role in iron metabolism. but its regulation has not
been characterized physiologically in vivo in humans. In
particular. why serum iron is elevated and RE cells are
much less iron-loaded than parenchymal cells in idiopathic
hemochromatosis is not known. The processing of erythro-
cyte iron by the RE system was studied after intravenous
(IV) injection of “Fe heat-damaged RBCs (HDRBCs) and
‘Fe transferrin in normal subjects and in patients with iron
deficiency. idiopathic hemochromatosis. inflammation.
marrow aplasia. or hyperplastic erythropoiesis. Early
release of “Fe by the RE system was calculated from the
plasma iron turnover and the “Fe plasma reappearance
curve. Late release was calculated from the ratio of “Fe/
‘Fe RBC utilization in 2 weeks. The partitioning of iron
between the early (release from heme catabolism) and late
(release from RE stores) phases depended on the size of RE
T HE RETICULOENDOTHELIAL (RE) system plays a
central role in iron metabolism, processing hemoglobin
iron from senescent RBCs.’T In normal conditions, the RE
system provides most of the iron required for erythropoiesis,6
and iron storage and release by the RE system are in
equilibrium.
We previously reported a method using trace amounts of
59Fe heat-damaged RBCs (HDRBCs) to investigate RE iron
kinetics in dogs.7 A model of iron transport by the RE system
could be derived from that study. After an initial processing
period required for heme catabolism, iron enters a labile pool
from which it is either promptly returned to the plasma or
incorporated into RE stores. Two distinct phases of radioiron
release were observed: the early phase (immediate release
from heme catabolism), which is completed within a few
hours, and the late phase (release from RE stores), which
develops over a period of days and weeks.
We characterized RE iron kinetics in humans, with a trace
dose of a physiologic RE tag. We explored normal subjects as
well as patients with various disorders of iron metabolism
and/or erythropoiesis, including iron deficiency, inflamma-
tion, idiopathic hemochromatosis, marrow aplasia, and
hemolysis. Iron transport in the RE system was quantified,
and factors regulating RE iron release were identified.
Investigation of patients with idiopathic hemochromatosis
was of particular interest, because the reason why RE cells
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iron stores. as illustrated by the inverse relationship
observed between early release and plasma ferritin
(p < .001 ). There was a strong correlation between early
release and the rate of change of serum iron levels during
the first three hours in normal subjects (r = .85. P < .001).
Inflammation produced a blockade of the early release
phase. whereas in idiopathic hemochromatosis early
release was considerably increased as compared with
subjects with similar iron stores. Based on these results.
we describe a model of RE iron metabolism in humans. We
conclude that the RE system appears to determine the
diurnal fluctuations in serum iron levels through variations
in the immediate output of heme iron. In idiopathic
hemochromatosis. a defect of the RE cell in withholding
iron freed from hemoglobin could be responsible for the
high serum iron levels and low RE iron stores.
S 1989 by Grune & Stratton. Inc.
are relatively free of iron overload and serum iron is elevated
in this condition is not known.8
MATERIALS AND METHODS
Experimental subjects. Twelve normal male volunteers and 28
patients were studied (Table I ). Two patients had iron deficiency.
Inflammation in nine patients was secondary to pneumonia (one),
Dressler’s syndrome after myocardial infarction (one), temporal
arteritis (one), rheumatoid arthritis (five), or undetermined (one).
The patients had a mean (±SD) WBC count of 8,100 ± l,080/.ol,
erythrocyte sedimentation rate (ESR) of 62 ± 8 mm/hr, and
fibrinogen of 6.7 ± 0.4 g/L. Eight patients had idiopathic hemo-
chromatosis. Three had iron overload with tissue damage (subjects
24, 25, and 26), and two had no tissue damage (subjects 27 and 28).
Subjects 24, 25, 27, and 28 were studied at diagnosis. Subject 26 was
studied 1 year after he discontinued an incomplete phlebotomy
program, subject 29 was studied while being regularly phleboto-
mized, and subjects 30 and 3 1 were studied 4 months after phle-
botomy therapy was discontinued, when iron stores had returned to
normal. Three patients with marrow aplasia were included, of whom
two had aplastic anemia. The first (subject 32) had received -40 L
transfused blood in 3 years and developed acute myelogenous
leukemia (AML) 4 months after the study. The other had received 2
L transfused blood (subject 33). The third patient had marrow
aplasia after melphalan therapy for multiple myeloma but had never
been transfused. Finally, six patients with hyperplastic erythropoie-
sis, due to hemolysis and/or ineffective erythropoiesis, were studied.
Two had fl-thalassemia minor, one had fl-thalassemia intermedia,
two had autoimmune hemolytic anemia, and one had megaloblastic
anemia. Only one of them had been transfused (subject 39). The
others had a mean plasma ferritin level of 2 13 ± 66 ng/mL.
Radioactive tags. “Fe-labeled transferrin was obtained as fol-
lows. Ten milliliters plasma were incubated for 30 minutes at 37#{176}C
with 0.5 to 0.8 iaCi/kg body weight of #{176}TFeC13(specific activity 10
oCi/zg iron) previously mixed with 4% sodium citrate to ensure a
molar ratio of citrate to iron of 50: 1 . The subject’s own plasma was
used except in patients with idiopathic hemochromatosis or marrow
aplasia, for whom a normal donor plasma was used.
#{176}9Fe-Labelednonviable HDRBCs were prepared in the following
manner. Ten milliliters normal plasma were incubated with 09FeC13
as described above and injected intravenously (IV) into a donor
subject to obtain a circulating activity of -.50,000 cpm/mL whole
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32 4.836 230 240 0.57
33 867 240 264 0.62
34 246 250 281 0.67
Mean 1,983 240 262 0.62
SEM 1.438 6 12 0.03
































45 89 65 0.83
56 70 48 0.82
204 120 iOO 0.68
68 148 94 0.98
60 152 100 0.93
110 150 124 0.69
72 122 102 0.72
90 126 101 0.75
97 138 85 0.89
128 45 51 0.50
108 100 68 0.91
29 120 95 0.77
89 115 86 0.79
13 10 7 0.03
15 27 22 0.83
14 22 26 0.59
15 25 24 0.71
1 3 2 0.12
199 38 39 0.59
135 41 48 0.52
231 20 30 0.46
655 55 53 0.71
92 25 14 1.10
77 30 26 0.71
165 40 29 0.92
425 30 23 0.94
314 23 21 0.79
254 34 31 0.75































































































































71 149 80 1.20
167 102 62 1.10
152 195 109 1.30
215 70 21 2.70
1.640 123 43 2.10
462 247 58 3.20
451 148 62 1.93
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where WB is whole blood, 0/2 is the clearance half-time of transferrin
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blood. Two donors were selected according to the following criteria:
(a) vegetative state and life expectancy not exceeding a few months;
(b) normal marrow function as assessed by PB cell counts; (c) blood
compatible with the largest number ofpotential recipients (ideally 0
Rh - ); (d) normal liver function tests and negative serology for
hepatitis and syphilis; (e) absence of antecedent or current hepatitis
or neoplasia. The HIV status of the donors was not tested because
the study was performed long before the first case of AIDS was
reported. Both donors were admitted for cerebral thrombosis. They
died 3.5 and 4 months after admission, respectively. The injection of
59Fe produced no effect on their hematologic parameters. Compati-
bility between the donor and recipient was checked by cross-match
test. At least ten days after the 59Fe injection, donor blood was drawn
on heparin and plasma was removed by centrifugation. The RBCs of
I mL whole blood were washed three times in 4 mL saline,
resuspended in 4 mL ACD formula A (8 g citric acid, 22 g sodium
citrate, 22.3 g dextrose per liter), and heated to 46#{176}Cfor nine
minutes. After cooling on ice, the RBCs were washed three times
with saline at room temperature, resuspended in saline, and injected
within 30 minutes.
Experimental procedures. Experimental subjects were fasted
overnight. “Fe Transferrin and 59Fe HDRBCs were injected IV
simultaneously, between 10:30 and I 1:30 AM, on day 0. Blood
samples (5 mL) were drawn from the opposite arm through an inline
catheter at 5, 10, 15, 30, 45, 60, 90, 120, 140, 160, 180, 210, 240,
270, 300, 360, and 420 minutes after injection. 59Fe Activity was also
monitored by external counting over the spleen, liver, and sacrum by
scintillation detectors. Radioactivity was measured for 60 minutes
after injection and for ten minutes at 240 and 420 minutes on day 0.
Blood samples (5 mL) and external counting were also obtained on
eight to ten occasions in a 2-week period.
Ferrokinetics. The plasma iron turnover (PIT) was calculated
according to the standard formula6:
PIT (mg/dL WB/day)
SeFe(ig/dL) x (100 - Hct x 0.9)/l00 1)
t2
“Fe, and 0.9 is the correction for trapped plasma in the Hct
(hematocrit) (0.98) and to convert venous Hct to whole body Hct
(0.92).
Plasma activity was extrapolated to 0 time, and RBC utilization
(RCU) at day N was calculated by the formula:
RCU (%)
cpm/mLWBatdayN 100
. x , (2)
cpm/mL plasma at 0 time (100 - Hct x 0.9)
RE iron kinetics. The calculation of early RE release of radioi-
ron was based on the rate of clearance of “Fe transferrin and the
reappearance curve of transferrin 59Fe derived from HDRBCs (Fig
IA). If X represents the amount of “Fe which reappeared in the
plasma at any time (percentage of dose injected), then:
X(t) = j;t R(t - z)G(z) dz, (3)
where R is the “Fe transferrin disappearance curve (percentage of
dose injected), G is the rate of entry into the plasma of 59Fe released
by the RE system (percentage of dose injected per minute), and z is
the total time from injection to appearance of 59Fe on transferrin; z =
y + x, where y is the time from injection to uptake by the RE system
and x is the transit time within the RE. The convolution equation
[eq. 3] was solved by a computer to obtain G from the experimental
curves R and X. Because 59Fe in HDRBCs is not immediately taken
up by the RE system and disappears from circulation according to an
exponential curve of slope r, then:
F(t) = G(t) - G’(t)/r, (4)
where F represents the rate of entry into the plasma of 59Fe released
by the RE system (percentage of dose injected per minute) if 59Fe
uptake by the RE system is immediate. G’ is the derivative of G.
Integration of F(t) with respect to time gives a hypothetical plasma
59Fe radioactivity time curve P(t) which represents the pattern of
accumulation of 59Fe in the plasma that would occur in the absence
of uptake by tissues. In all studies, F(t) had declined to virtually 0 by
420 minutes, resulting in a plateau of P(t). The value of P(420) was
therefore considered equal to P(x) and taken as the proportion of
Fig 1 . RE iron kinetics in a normal subject. (A)
Transferrin “Fe plasma disappearance curve (0).
and ‘Fe plasma disappearance as HDRBCs and
reappearance as transferrin (#{149}).(B) Rate of entry
G(t) into the plasma of MFe released by the RE
system expressed as percent of dose per minute
multiplied by 1 00 (0). and hypothetical plasma “Fe
radioactivity time curve P(t) that would occur in
the absence of uptake by tissues. (#{149}).
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59Fe release, most of this early release takes place in the first
two hours. A plateau is reached after five to seven hours,
indicating that early release is virtually terminated by that
time. Analysis of the RCU curve over a 2-week period
demonstrated a further (late phase) release of 59Fe by the RE
cell with a t’/2 of 6 ± 1 days, involving 34% ± 3% of the
activity injected. The sum of early and late releases, calcu-
lated independently, accounted for 97% (range 90% to
107%) of the radioactivity injected as HDRBCs. As deter-
mined by the ratio of 59Fe/55Fe RCU, 92.9% of the 59Fe had
been released after the second week, and >99% had been
released after the third week. External counting demon-
strated a rapid uptake of 59Fe HDRBCs by the spleen and
liver, followed by a quick release of >50% ofthe activity (Fig
3). Thereafter, radioactivity over the two organs remained
50- unchanged because increasing circulating RBC activity com-
pensated for the late 59Fe release by the RE system.
Although there was no correlation of the percentage of early
release with the initial serum iron level, a highly significant
association was found with the rate of change of serum iron
10- level during the first three hours (r - .85,p < .001) (Fig 4).
There was also a significant negative correlation between the
D i  I  I percentage of early release and plasma ferritin (r = - .70,
0 5 10 15 20 P<.01)(Fig5).
RE radioiron release was also studied in a variety of
DAYS disorders of iron metabolism (Table 1). Two patients with
iron deficiency had 102% ± 1% of the radioiron injected as
HDRBCs released in the early phase (P < .05 by Wilcoxon
rank sum test), with a t’/2 similar to that of the normal
subjects. The 59Fe and 55Fe RCU curves were identical,
indicating no iron release in the late phase.
Eight patients with inflammation were studied. As com-
pared with normal subjects, they had significantly lower
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iron released in the early phase. After 180 minutes, F(t) could be
described by an exponential curve, the t’/2 of which was used to
characterize the speed of early release (Fig I B). The mean transit
time (TT) of the early phase was defined as:
f’. tF(t)
TT(minutes) - #{176}1’
The lag period was calculated by subtracting the mean release time
(release t’/2 x 1 .44) from the TT. The late RE release was calculated
from the cumulative “Fe and “Fe RCU over a 2-week period (Fig
2A). The ratio of 59Fe/55Fe RCU at time t represents the total
fraction of “Fe released by the RE system (early release + late
release at time t). When the complement of this ratio was plotted
against time on a semilogarithmic paper (Fig 2B), late release
appeared to be a single exponential curve. The proportion of the
injected dose released in the late phase was obtained by extrapolat-
ing the curve back to the half-reappearance time of “Fe in the RBC
mass. The t’/2 of the exponential, determined by least squares,
represents the speed of late release. Formal proof of this method has
been discussed previously.7
Miscellaneous. Serum iron and total iron binding capacity
(TIBC) were measured by standard procedures.9”#{176} Serum iron was
measured at zero, one, two, three, five, and seven hours after
injection, and the rate of change (zg/dl/h) during the first three
hours was determined from the slope of the regression line fitted
through serum iron values at zero, one, two, and three hours. Plasma
ferritin was measured by a radioimmunoassay (RIA).H Hemoglobin
(Hb), WBC, and platelet counts were measured in a Coulter S
Counter (Coulter Electronics Inc, Hialeah, FL). Hct was measured
by the micromethod.
Blood samples were processed by a modification of the method of
Eakins and Brown,’2 and radioactivity was measured in a liquid
100-
50
Fig 2. Late release in a normal subject. (A) RBC utilization of
transferrin “Fe (0) and HDRBCs “Fe (s). and ratio of “Fe/”Fe
(percentage) in the RBC mass (U) in 3 weeks. (B) Late RE release.
The complement of the “Fe/”Fe ratio in the RBC mass was
plotted against time (#{149}).The t’/ of the curve represents the speed
of late release. The proportion of the injected “Fe released in the
late phase was obtained by extrapolating the curve back to the
half-reappearance time of “Fe in the RBC mass (a).
0-
scintillation counter with appropriate correction for cross-counting.
Background activity and standards were measured in triplicate.
Statistical significance of the differences observed between normal
subjects and groups of patients was assessed by Student’s t-test or by
Wilcoxon rank sum test when the number of patients was very
small.
(5) Consent. The University of Liege Human Subjects and Ethic
Committee was not formed at the time of the study. Therefore, a
special committee was established, including the heads of the
departments of internal medicine and neurology and the senior
attending physician on the neurology ward. The committee approved
of the experimental protocol and monitored selection of the donor
subjects. Informed consent was obtained from all experimental
subjects and from the families of the donor subjects.
RESULTS
The disappearance of HDRBCs from the circulation of the
recipient subject occurred as a single exponential with a 0/2 of
4.2 ± 0.3 minutes (mean ± SEM). Intravascular hemolysis,
as monitored by the activity present in the plasma 1 5 minutes
after injection, amounted to I .1% ± 0.1%.
Ferrokinetic and RE iron kinetic measurements in normal
subjects are shown in Table 1 . After a lag period of 40 ± two
minutes, 64% ± 4% (range 43% to 89%) of the activity
injected as HDRBCs was released into the plasma with a t’/2
of 33 ± 2 minutes. The mean transit time within the RE cell
was 86 ± 2 minutes. As shown in Fig I by the cumulative
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Fig 3. External counting over the spleen (0)
and liver (#{149}).in percentage of maximum uptake.
using scintillation detectors. Whole blood radloac-
tivity (---) is expressed as percentage of dose
injected.
serum iron levels and higher plasma ferritin levels. Early
release was reduced to 44% ± 5% (P < .001), and late release
increased to 58% ± 6% (P < .005). Although the mean
transit time and lag period were not changed significantly,
the t’/2 of early release (42 ± 3 minutes, P < .05) and the V/2
of late release ( I 2 ± 3 days, P < .05) were increased. The
relationship between the percentage of early release and
plasma ferritin (R = - .71, P < .05) for these patients is also
shown in Fig 5. No correlation was found between the
percentage of early release and ESR, fibrinogen, or
a2-globulin.
The pattern of radioiron release by the RE cell was also
analyzed in eight patients with idiopathic hemochromatosis.
The proportions of early release (51% to 60%) and late
release (37% to 48%) were rather constant in the six patients
studied before or during treatment. Thus, despite transferrin
saturation and increased iron stores, the early release phase
was within the normal range. The t1/2 of late release was
increased to relatively high values in the three patients with
moderate iron overload, to very high values in the two
patients with important iron overload, and to only I 5 days in
the patient heavily overloaded but being phlebotomized. In
the three patients with tissue damage, external counting
disclosed an accumulation of 59Fe over the liver, whereas the
clearance of iron from the spleen was normal. This indicated
early redistribution of iron processed by the spleen into the
hepatic parenchyma. The iron stores of two patients studied
after treatment had returned to normal levels; 90% and 94%
of the 59Fe activity was released in the early phase, and 8%
and 0% was released in the late phase, respectively.
Three patients with marrow aplasia had a saturated
circulating transferrin. The proportion of radioiron released
in the early phase was 22%, 25%, and 52%, respectively
(P < .02 by Wilcoxon rank sum test). Late release could not
be determined because of the absence of significant RCU.
Six patients presented hyperplastic erythropoiesis and
thus increased amounts of iron entering the RE system
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CHANGE IN PLASMA IRON (jJG/100 ML/H)
Fig 4. Correlation in normal subjects between early release
and rate of change of serum iron level during the first three
hours.
Fig 5. Correlation between percentage early release and
plasma ferritin in normal conditions (0). iron deficiency (A).
inflammation (#{149}).marrow aplasia (U). and idiopathic hemochroma-
tosis ( 0). The area between the two curves includes all but
idiopathic hemochromatosis subjects.
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Early release accounted for 53% ± 6% and late release for
39% ± 5% of the activity injected as HDRBC. The t1/2 of the
early (37 ± 2 minutes) and late (7 ± 2 days) phases did not
differ from the values observed in normal subjects. The only
discrepancy with normal subjects was noted in the patient
heavily transfused in whom the proportion of early release
was only 30%.
DISCUSSION
The present study is the only one to characterize iron
processing and release by the RE system in humans, using a
physiologic RE tag. The mean iron dose of 6 zg/kg body
weight is equivalent to the amount entering the RE system in
30 minutes under normal conditions. When a much higher
dose of HDRBCs (500 g Fe/kg) is injected, serum iron
levels are raised up to 300 ig/dL, thus redistributing part of
the radioiron to the hepatocyte.’3 However, 59Fe RCU in
three subjects who received only 10 ig Fe/kg was similar to
our findings.’3 On the other hand, colloidal iron is catabo-
lized more slowly than RBC iron, and iron in some big
particles may not be available at all.’4
In contrast to methods based on a preestablished multi-
compartmental model,’5 the present method is independent
of any assumption, except that HDRBCs are cleared by the
RE system and that all radioiron released is returned to the
plasma. A lag period of =40 minutes, presumably required
for phagocytosis of HDRBCs and heme catabolism, was
observed in normal subjects as well as in patients. In normal
conditions, two thirds of the radioiron freed from Hb were
promptly returned to the plasma with a t’/2 of 33 minutes, and
one third was incorporated into RE stores and released at a
much slower rate (t’/2 = six days). Two distinct phases of
radioiron release were also identified by external counting
(Fig 3). This biphasic rate of release has also been recognized
in macrophage cultures.’8 The difference in rate of mobili-
zation of RE storage iron and newly catabolized heme iron is
consistent with the observation that normal individuals phle-
botomized to an Hct of 25% to 30% will deliver a maximum
of 40 to 60 mg storage iron per day to the marrow, whereas
iron supply from hemolyzed RBCs is much more efficient.’9
Most’6’#{176}2’ but not all22 in vitro studies with macrophages
have failed to show any effect of excess apotransferrin or of
transferrin saturation on RE iron release. Injection of a large
dose of apotransferrin in animals did not modify iron dona-
tion by tissues.23’24 Saturating plasma transferrin in dogs7 or
in humans’3 did not change iron release by the RE cell.
Similarly, we and other investigators’5 observed no correla-
tion between the initial plasma iron level and the early phase
of RE radioiron release.
However, in normal subjects, there was a strong correla-
tion between the percentage of early release and the rate of
change of serum iron in the three hours after injection of
HDRBCs (Fig 4). A mean rate of change of 10 ,g/ 100 mL
corresponded to 18.1% early release. The total flux of iron
through the RE system represents 80% of the PIT (ie, 44.5
sg/100 mL/h). Therefore, 80% of the variation of serum
iron can be accounted for by changes in the percentage of
early release (44.5 x 18.1/100 = 8 tg/100 mL/h). This
indicates that the RE activity is responsible for most of the
diurnal variations in serum iron levels.725
It is important to make the distinction between radioiron
release as we define it and the absolute iron output from the
RE cell. Thus, because radioiron is diluted in a higher iron
input into the RE system, the normal percentage of early
radioiron release in patients with hemolysis or ineffective
erythropoiesis means that the absolute amount of iron
released by the RE system is enhanced in such cases.
Hypertransfusion23 or aplasia reduces, whereas venesec-
tion,23 exchange transfusion with reticulocytes,24 or erythroid
hyperplasia enhances iron release by the RE cell. Patients
with marrow aplasia still showed significant early release
despite transferrin saturation and suppression of erythro-
poiesis. This 22% early release could represent a limit for the
ability of the RE system to retain iron from digested RBCs.
Although marrow requirements largely influence the total
amount of iron leaving the RE system, the importance of RE
iron stores appears to influence the partitioning of radioiron
between the early and late release phases. When iron stores
are absent, as in iron deficiency, iron ouput is totally
contributed entirely by recently digested RBCs.’3’426’27
When RE iron stores increase, RE radioiron release
decreases,23 and this was particularly true for early release
(Fig 5). This was also observed in rats in which the percent-
age of early release (ER) and the rate of late release were
inversely related to the amount of ferritin iron in the spleen
(0. Fillet, unpublished observations, July 1977).
The following model of RE iron metabolism in humans
can thus be proposed. Iron output from the RE system is
responsible for diurnal variations of serum iron levels. How-
ever, the total amount of iron leaving the RE system remains
relatively constant over time under basal conditions. When
body (marrow) requirements are enhanced, more iron is
donated, particularly through an increase in the immediate
output of heme iron. When body (marrow) requirements are
decreased, iron supply is diminished. Plasma iron levels
decrease when marrow requirements cannot be matched by
iron mobilization and increase when marrow activity is not
sufficient to use the minimum amount of iron the RE cell is
not able to retain. When the amount of iron entering the RE
system is increased by transfusions and erythropoiesis is not
stimulated to a similar extent, the RE cell will accumulate
storage iron.
However, abnormalities in regulation of RE activity can
appear in certain diseases. RE iron output is reduced by
inflammation.’323’26’23’ The negative correlation of the per-
centage of early release with plasma ferritin (Fig 5) and the
absence of correlation with the biologic markers of inflam-
mation apparently indicate that early release is decreased
because RE stores are increased and not because of the
intensity of inflammation itself. However, hyposideremia
occurs within hours of inflammation,3t32 when the iron
content of RE cells cannot yet be increased.32 Ferritin
production is enhanced in inflammatory RE cells,29’33 and
this precedes the decrease in serum iron levels. Thus,
increased ferritin synthesis (as a nonspecific acute-phase
reactant?) may be a mechanism accounting for the reduction
in iron output from the RE cell.29
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Idiopathic hemochromatosis is characterized by high
serum iron levels even before significant iron overload has
developed.8 The high transferrin saturation is responsible for
a progressive iron loading of the hepatocytes.34 IH patients
with limited iron stores released >90% of HDRBC radioiron
in the early phase, whereas those with heavy stores still had a
normal percentage of early release. At each ferritin level,
early release was much higher in idiopathic hemochromato-
sis patients than in the other patients with similar plasma
ferritin levels (Fig 5). However, the rate of late release
appeared to be related to the size of iron stores. These results
suggest that the RE cell in idiopathic hemochromatosis could
have a defect in withholding iron freed from Hb that would
explain the high serum iron levels observed early in the
course of the disease and the relatively low RE iron stores.
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heme iron from senescent RBCs, any reduction in transferrin
iron uptake would probably not be of sufficient magnitude to
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